替奈普酶桥接治疗大血管闭塞性卒中的功能结局、再通与出血率
该回顾性研究纳入588例接受0.25 mg/kg替奈普酶静脉溶栓后行血管内治疗的大血管闭塞性急性缺血性卒中患者,其中88%为二次转运。3个月功能独立率为47%,症状性颅内出血率为2.5%,最终再通率为83.7%。
要点
- 替奈普酶桥接治疗在真实世界中安全有效,3个月功能独立率达47%。
- 症状性颅内出血率低(2.5%),最终再通率高(83.7%)。
- 直接入院与二次转运患者的再通率相似,支持更广泛使用桥接治疗。
核心结论
- 替奈普酶在机械取栓前用于大血管闭塞性卒中患者是安全有效的,可实现快速再通。
研究设计与样本
- 回顾性分析588例接受0.25 mg/kg替奈普酶静脉溶栓(发病270分钟内)后行脑血管造影的大血管闭塞性急性缺血性卒中患者。
主要发现
- 3个月功能独立(改良Rankin量表评分≤2)率为47%(269/570,95%CI 43.0-51.4)。
- 取栓前再通(改良脑缺血治疗评分2b-3)率为20.4%(120/588,95%CI 17.2-23.9)。
- 最终再通率为83.7%(492/588,95%CI 80.4-86.6)。
- 症状性颅内出血率为2.5%(14/567,95%CI 1.4-4.1)。
- 直接入院与二次转运患者的取栓前再通率相似(20.6% vs 20.4%,p>0.99)。
临床怎么用
- 替奈普酶桥接治疗可在日常实践中安全用于二次转运或直接入院的大血管闭塞性卒中患者。
- 研究结果支持更广泛地使用替奈普酶作为桥接治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: To investigate in routine care the efficacy and safety of IV thrombolysis (IVT) with tenecteplase prior to mechanical thrombectomy (MT) in patients with large vessel occlusion acute ischemic strokes (LVO-AIS), either secondarily transferred after IVT or directly admitted to a comprehensive stroke center (CSC). METHODS: We retrospectively analyzed clinical and procedural data of patients treated with 0.25 mg/kg tenecteplase within 270 minutes of LVO-AIS who underwent brain angiography. The main outcome was 3-month functional independence (modified Rankin Scale score ≤2). Recanalization (revised Treatment in Cerebral Ischemia score 2b-3) was evaluated before (pre-MT) and after MT (final). RESULTS: We included 588 patients (median age 75 years [interquartile range (IQR) 61-84]; 315 women [54%]; median NIH Stroke Scale score 16 [IQR 10-20]), of whom 520 (88%) were secondarily transferred after IVT. Functional independence occurred in 47% (n = 269/570; 95% confidence interval [CI] 43.0-51.4) of patients. Pre-MT recanalization occurred in 120 patients (20.4%; 95% CI 17.2-23.9), at a similar rate across treatment paradigms (direct admission, n = 14/68 [20.6%]; secondary transfer, n = 106/520 [20.4%]; p > 0.99) despite a shorter median IVT to puncture time in directly admitted patients (38 [IQR 23-55] vs 86 [IQR 70-110] minutes; p < 0.001). Final recanalization was achieved in 492 patients (83.7%; 95%CI 80.4-86.6). Symptomatic intracerebral hemorrhage occurred in 2.5% of patients (n = 14/567; 95% CI 1.4-4.1). DISCUSSIONS: Tenecteplase before MT is safe, effective, and achieves a fast recanalization in everyday practice in patients secondarily transferred or directly admitted to a CSC, in line with published results. These findings should encourage its wider use in bridging therapy. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that tenecteplase within 270 minutes of LVO-AIS increases the probability of functional independence.
引用
- Gerschenfeld G, Smadja D, Turc G, et al. Functional Outcome, Recanalization, and Hemorrhage Rates After Large Vessel Occlusion Stroke Treated With Tenecteplase Before Thrombectomy. Neurology. 2021. PMID: 34635558. doi:10.1212/WNL.0000000000012915
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。